12:00 AM
 | 
Aug 27, 2007
 |  BioCentury  |  Emerging Company Profile

PregLem: New spin in gynecology

PregLem S.A. is tackling the genitourinary and reproductive space with a mix of novel compounds and new formulations of existing products. For the former, the company thinks it should have safety and efficacy advantages. For its improved formulations, convenience is the selling proposition.

PregLem spun out of Ipsen Group in 2006 with the goal of in-licensing compounds in preclinical and clinical development and taking them to market.

In June, the company raised CHF32 million ($26 million) in a series A round led by Sofinnova Partners and co-led by NeoMed and MVM Life Science Partners. The bolus of cash triggered a deal with Ipsen (Euronext:IPN, Paris, France), which granted PregLem an exclusive worldwide license to PGL2001 and PGL1001. IPN, which is eligible for royalties, has an undisclosed...

Read the full 639 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >